How Smart Money Is Trading United Therapeutics Corporation (UTHR)

Page 1 of 2

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at United Therapeutics Corporation (NASDAQ:UTHR) from the perspective of those elite funds.

United Therapeutics Corporation (NASDAQ:UTHR) has experienced a decrease in activity from the world’s largest hedge funds lately. The stock was in 34 hedge funds’ portfolios at the end of the third quarter of 2015. In comparison, there were 41 hedge funds in our database with UTHR positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Flextronics International Ltd. (NASDAQ:FLEX), Xylem Inc (NYSE:XYL), and SVB Financial Group (NASDAQ:SIVB) to gather more data points.

Follow United Therapeutics Corp (NASDAQ:UTHR)

At the moment there are a large number of methods market participants use to value their holdings. A duo of the most useful methods are hedge fund and insider trading interest. Our researchers have shown that, historically, those who follow the top picks of the elite hedge fund managers can outpace the S&P 500 by a superb amount (see the details here).

Keeping this in mind, let’s go over the new action encompassing United Therapeutics Corporation (NASDAQ:UTHR).

How have hedgies been trading United Therapeutics Corporation (NASDAQ:UTHR)?

At Q3’s end, a total of 34 of the hedge funds tracked by Insider Monkey held long positions in this stock, a drop of 17% from one quarter earlier. With the smart money’s sentiment swirling, there exists a select group of notable hedge fund managers who were boosting their holdings considerably (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Matt Sirovich and Jeremy Mindich’s Scopia Capital has the number one position in United Therapeutics Corporation (NASDAQ:UTHR), worth close to $373.5 million, corresponding to 8% of its total 13F portfolio. Sitting at the No. 2 spot is Iridian Asset Management, run by David Cohen and Harold Levy, which holds a $258.7 million position; 2.2% of its 13F portfolio is allocated to the stock. Other members of the smart money community that hold long positions comprise William Leland Edwards’s Palo Alto Investors, Cliff Asness’s AQR Capital Management and Jim Simons’s Renaissance Technologies.

Page 1 of 2